Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.
Metrics to compare | CINPHA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCINPHAPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.0x | 0.0x | −0.5x | |
PEG Ratio | −0.10 | 0.00 | 0.00 | |
Price/Book | 1.6x | 0.0x | 2.6x | |
Price / LTM Sales | 180.9x | 0.0x | 3.3x | |
Upside (Analyst Target) | 247.2% | 0.0% | 43.5% | |
Fair Value Upside | Unlock | 0.0% | 6.8% | Unlock |